Hong Kong stocks are on the move | BeiGene (06160.HK) rose over 4% in early trading period. The positive results of MANGROVE Phase 3 clinical trial. It is planned to apply for approval in the second half of the year.
According to the AI Finance App, BeiGene (06160.HK) surged over 4% in the morning trading session, rising 4.58% as of the time of writing to HK$182.7, with a trading volume of HK$81.5571 million.
Latest
